ENDO-205: the first non-hormonal endometriosis treatment enters clinical trials

If you live with endometriosis, you’ve probably been offered hormonal treatment: birth control pills or IUDs, GnRH agonists, progestins. For some women, these work. For others, the side effects are intolerable, the relief is partial, or hormonal treatment conflicts with their reproductive plans. And for many, being told that hormones are the only medical option feels like being offered a single key for a lock that doesn’t quite fit.

That’s why the FDA’s clearance of an Investigational New Drug (IND) application for ENDO-205 caught our attention. Developed by EndoCyclic Therapeutics, it’s the first non-hormonal drug candidate designed for endometriosis to enter clinical trials in the United States.

What ENDO-205 is

Details on the drug's mechanism remain limited at this early stage. What's public is that ENDO-205 is a non-hormonal compound, meaning it doesn't work by suppressing ovulation, lowering estrogen, or otherwise altering the hormonal environment. The FDA's IND clearance means the agency has reviewed the preclinical safety data and approved the drug to be tested in humans, not that it will work.

This is the very beginning of the clinical trial process. An IND clearance doesn’t mean the drug works, and it doesn’t mean it will reach the market. It means there’s enough evidence of safety and biological reasoning to justify testing it in people: that process will take years.

But the significance for us isn’t in the timeline; it’s about the fact that a non-hormonal option for endometriosis is something many women have been asking for, and something the pharmaceutical industry has been slow to deliver.

Why non-hormonal options matter

Current medical treatments for endometriosis are dominated by hormonal approaches. These can be effective for managing pain, but they come with trade-offs.

GnRH agonists (like Lupron) suppress estrogen to menopausal levels, which can reduce endometriotic lesion activity but produces side effects like hot flashes, bone density loss, and mood changes (and its use is actually recommended for only a limited time to avoid these side effects, which means it can’t be a long-term solution anyway). Progestins and combined oral contraceptives manage pain for many women but can cause weight gain, mood changes, and breakthrough bleeding. And all hormonal treatments prevent pregnancy during use, which is a dealbreaker for women trying to conceive.

There’s also a growing recognition that hormonal treatments manage the experience of endometriosis without addressing its underlying mechanisms. Research published in recent years has shown that endometriosis involves immune dysfunction (neutrophils signaling incorrectly and failing to clear debris), neuroinflammation, and central pain sensitization, none of which are directly addressed by suppressing hormones.

A non-hormonal approach that targets one or more of these mechanisms would represent a fundamentally different treatment strategy.

What else is in the non-hormonal pipeline

ENDO-205 isn’t the only non-hormonal approach being studied. The landscape is broader than many people realize.

Neurostimulation. Brain stimulation for endometriosis-related chronic pelvic pain is being investigated in multiple clinical trials. Samphire Neuroscience is running three: ENHANCE (NHS collaboration, double-blind sham-controlled), HOPE (UFRN collaboration, targeting pain, fatigue, and quality of life), and RELIEF (US-based, decentralized, double-blind sham-controlled). Nettle™ uses gentle brain stimulation targeting the motor cortex for pain and the DLPFC for mood, addressing the central sensitization component of endometriosis pain. Thousands of women have already tried neurostimulation for endometriosis-related pain outside of trial settings, and you can read about their experiences on Trustpilot.

Immunomodulation. Endometriosis involves immune dysfunction, including aberrant signaling in neutrophils and macrophages that may allow endometrial-like tissue to survive and grow outside the uterus. Several preclinical and early-stage clinical programs are exploring drugs that aim to recalibrate this immune response directly, rather than working around it through hormone suppression. The 2025 review in Journal of Clinical Medicine outlines a number of candidate targets in this area.

Anti-inflammatory and anti-angiogenic agents. Endometriotic lesions rely on new blood vessel formation (angiogenesis) and produce inflammatory signals that drive pain. Drugs that target these processes, including some repurposed from other inflammatory conditions, are at various stages of investigation. None are approved for endometriosis specifically yet, but the underlying biology is well established.

Central pain modulation. A growing body of research recognizes that endometriosis pain is shaped by central sensitization, meaning the brain's pain-processing networks become more reactive over time. Approaches that target these networks, whether pharmacological or neuromodulatory, do not address the lesions themselves but can change the experience of pain in ways that hormonal treatments cannot.

What this means in practice

For someone living with endometriosis right now, ENDO-205 will not change anything in the immediate term. Clinical trials take years, and most candidates that enter trials do not reach the market. But the IND clearance is a meaningful signal that the field is starting to take non-hormonal options seriously. The pipeline is broadening, and the women who have been asking for options beyond hormones are finally being heard.

The biology of endometriosis is more complex than the hormonal frame has allowed for. As the science of immune dysfunction, neuroinflammation, and central sensitization develops, the treatment options should expand to match. ENDO-205 is one step in that direction.